The cheapest legitimate way to get tirzepatide, as of October 2026, is a covered commercial plan plus Lilly’s savings card, as little as $25 a month. Paying cash, Zepbound self-pay through LillyDirect costs $299 to $449 by dose; eligible Medicare patients pay up to $50. Compounded tirzepatide costs less but is not FDA-approved.
Tirzepatide is the molecule in both Mounjaro and Zepbound, and the question people actually type is blunter than either brand name: what is the cheapest legitimate way to get it? There is a real answer, but it comes with a caveat you should read before the numbers: the cheapest options usually buy their lower price by trading away some regulatory assurance. Here is the honest map of the routes, with figures checked against Lilly’s own pages in October 2026.
What is the cheapest way to get tirzepatide without insurance?
The lowest-cost route that is still branded, FDA-approved tirzepatide is Lilly’s own self-pay channel, sold through LillyDirect as Zepbound single-dose vials or the multi-dose KwikPen. Priced by dose as a 4-week supply, both run $299/month for 2.5 mg, $399 for 5 mg, and $449 for 7.5 mg and above.[5]There is a catch worth flagging: the $449 price on the higher doses depends on refilling within 45 days of your previous delivery. Miss that window and the regular price applies: $499 for 7.5 mg and $699 for 10 mg and up.[5] The 2.5 mg dose is a starter strength, not a maintenance dose, so most people settle at the $449 tier. This is the same drug you would get at a pharmacy, sold directly by Lilly; the vial needs a syringe and the KwikPen needs pen needles, both bought at checkout. Mounjaro, the diabetes brand, is also sold self-pay through LillyDirect, at $499 a month at every dose.[5] We walk through the mechanics of ordering it in how to get Zepbound.
Can the savings card get tirzepatide to $25 a month?
If you have commercial insurance that covers Zepbound, the manufacturer savings card is usually the cheapest legitimate route of all, bringing the copay down to as little as $25 for a 1-, 2-, or 3-month fill.[1] The fine print matters: savings are capped at $100 per month (up to $300 for a 3-month fill), with a separate annual maximum of $1,300, and the current card expires December 31, 2026.[1] Crucially, the card is for commercial insurance only — anyone on Medicare, Medicaid, the VA, DOD or TRICARE is excluded by its terms.[1] Medicare patients have their own route for weight management: under the Medicare GLP-1 Bridge, a CMS demonstration running from July 1, 2026 to December 31, 2027, eligible Part D patients can get the Zepbound KwikPen for no more than $50 a month (vials and the single-dose pen are not covered).[6] Whether your plan covers it at all is the whole ballgame, and that is exactly where out-of-pocket cost is really decided.
Why coverage, not the sticker, sets your real cost
Branded tirzepatide carries a list price of more than $1,000 a month for a 28-day supply (about $1,086 for Zepbound pens and $1,112 for Mounjaro).[2] But list price is a sticker, not a bill — almost no one pays it. What you actually pay is a function of insurance: a covered commercial plan plus the savings card can mean ~$25/month; an uncovered plan pushes you to the ~$449 self-pay price; Medicare patients who qualify for the GLP-1 Bridge pay up to $50; and Medicaid coverage for weight loss depends on your state. The mechanics of formularies, prior authorization and step therapy — the things that decide whether you pay $25 or $1,000 — are laid out in our explainer on GLP-1 cost and insurance coverage. And if you are weighing the two Lilly brands, the choice rarely changes the molecule but often changes the coverage; see Mounjaro vs Zepbound.
Is compounded tirzepatide cheaper, and why?
Search “cheapest tirzepatide” and you will hit telehealth offers advertising compounded tirzepatide well below the branded self-pay price. It looks cheaper for concrete reasons: compounded drugs skip the branded manufacturer’s pricing entirely, are mixed by a pharmacy rather than produced under Lilly’s process, and — critically — are not FDA-approved. No compounded version has been reviewed for safety, efficacy, or manufacturing quality the way the branded product has. That missing review is the discount.
It is also a narrowing door. During the 2023–24 shortage, compounding tirzepatide was broadly permitted. But the FDA declared the tirzepatide shortage resolved, which ended the broad compounding exceptions. In February 2026 the FDA announced it intends to restrict GLP-1 ingredients meant for mass-marketed, non-approved compounded copies,[7] and on April 30, 2026 it went further, proposing to exclude tirzepatide (along with semaglutide and liraglutide) from the list of bulk substances that 503B outsourcing facilities may compound.[3] The practical takeaway: a cheap compounded offer in 2026 is operating in a shrinking, legally contested space, not a settled discount channel. If the narrowing pushes you to look elsewhere, start from the legitimate channels for buying tirzepatide rather than a gray-market seller. We lay out the full regulatory picture — and the honest risk tradeoff — in compounded vs branded GLP-1: the regulatory picture.
Why the cheapest sticker isn’t always the cheapest plan
Cost is not separate from whether the drug works, because tirzepatide only keeps working while you keep taking it. Real-world studies of why people stop GLP-1 and dual-agonist therapy find that cost and loss of coverage are among the leading reasons for discontinuation, alongside side effects.[4] Since stopping typically reverses much of the weight loss, an affordability gap functions as a treatment failure. A slightly cheaper route you have to abandon in three months is more expensive, in the way that counts, than a steadier one you can maintain.
The honest bottom line
If your commercial plan covers Zepbound, the savings card is likely the cheapest legitimate route, near $25 a month. If you are paying cash, LillyDirect self-pay Zepbound at $299–$449 by dose is the lowest-cost approved option, provided you refill on schedule. Compounded tirzepatide is cheaper on paper, but it is not FDA-approved and the legal pathway has narrowed — that is a price and a risk you should weigh with eyes open, not a free discount. Prices in this market move often, so verify the current figure on Lilly’s own pages before you budget. For a fuller breakdown of the branded numbers, see our Zepbound cost guide.